11 November 2015
EMA/PDCO/662503/2015
Procedure Management and Committees Support Division

Paediatric Committee (PDCO)

Minutes for the meeting on 7-9 October 2015

Chair: Dirk Mentzer – Vice-Chair: Koenraad Norga

7 October 2015, 08:30- 19:00, room 2A

8 October 2015, 08:30- 19:00, room 2A

9 October 2015, 08:30- 13:00, room 2A

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO meeting reports once the procedures are finalised and start of referrals will also be available.

Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes.

Further information with relevant explanatory notes can be found at the end of this document.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Table of contents

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced as included in the pre-meeting list of participants and restrictions.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 23 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

The agenda was adopted with amendments.

1.3. Adoption of the minutes

The minutes were adopted and will be published on the EMA website.

2. Opinions[1]

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.2. Opinions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

[1] Please refer to the October 2015 PDCO monthly report published on the EMA Website, see PDCO meeting reports

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan

2.4. Opinions on Re-examinations

2.5. Finalisation and adoption of opinions

3. Discussion of applications

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.2. Discussions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

4. Nominations

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

4.1. List of letters of intent received for submission of applications with start of procedure January 2016 for Nomination of Rapporteur and Peer reviewer

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver.

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.3. Nominations for other activities

None

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. Discussions on SAWP products with paediatric interest

6. Discussion on the applicability of class waivers

6.1. Discussions on the applicability of class waiver for products

6.1.1. AZD7624 - EMEA-40-2015

AstraZeneca AB; All classes of medicinal products for the treatment of chronic obstructive pulmonary disease (COPD) (excluding chronic lung diseases associated with long-term airflow limitation, such as asthma, bronchopulmonary dysplasia, primary cilia dyskinesia, obstructive lung disease related to graft-versus-host disease after (bone-marrow) transplantation)/ Treatment of chronic obstructive pulmonary disease (COPD)

Rapporteur: Birka Lehmann

Summary of committee discussion:

The applicability of the class waiver to the planned therapeutic indication was confirmed. Potential paediatric interest of this medicine suggested by PDCO: treatment of patients with asthma.

6.1.2. Momelotinib - EMEA-41-2015

Gilead Sciences International Ltd; Revised classes of medicinal products for the treatment of pancreatic malignant neoplasms/ Treatment of pancreatic adenocarcinoma

Rapporteur: Koenraad Norga

Summary of committee discussion:

The applicability of the class waiver to the planned therapeutic indication was not confirmed because momelotinib does not belong to the classes of the revised class waivers for the treatment of pancreatic malignant neoplasms as referred to in the Agency's Decision CW/0001/2015. However, in case of removal from the list of class waivers, the requirements set out in Article 7 and 8 of Regulation (EC) No 1901/2006 shall not apply for 36 months from the date of the removal from the list of class waivers.

A positive opinion for a paediatric investigation plan was already adopted for momelotinib (EMEA-001656-PIP01-14).

Other potential paediatric interest of this medicine suggested by PDCO: treatment of patients with solid tumours.

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver

None

8. Annual reports on deferrals

8.1.1. Adalimumab – Humira - EMEA-000366-PIP02-09

AbbVie Limited

Difficulties progressing the PIP? Yes

Summary of committee discussion:

The PDCO noted the report.

8.1.2. Adalimumab – Humira - EMEA-000366-PIP04-12

AbbVie Limited

Difficulties progressing the PIP? No

Summary of committee discussion:

The PDCO noted the report.

8.1.3. Adalimumab – Humira - EMEA-000366-PIP05-12

AbbVie Limited

Difficulties progressing the PIP? Yes

Summary of committee discussion:

The PDCO noted the report.

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

9.1.1. Debriefing on White Paper DG discussions and proposal for future steps of the PDCO

PDCO member: Koenraad Norga

Summary of committee discussion:

The Committee noted the latest version of the "White Paper" and discussed their input to the EC's 10 years report.

9.1.2. PDCO ORGAM dates for 2016

Summary of committee discussion:

The PDCO ORGAM meeting dates for 2016 were adopted. It was agreed to organise these virtual meetings in the afternoon to facilitate participation of PDCO delegates.

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

Summary of committee discussion:

The PDCO members were informed about 4 products, Elocta, Genvoya, Orkambi and Ravicti, for which the CHMP adopted a positive opinion recommending paediatric indications during their meeting in September 2015. A new pharmaceutical form (granules) in two new strengths (50 mg and 75 mg) for Kalydeco was approved to enable administration to children from 2 to less than 6 years of age.

9.2.2. Article 31 on Fusafungine: Pharmacovigilance Risk Assessment Committee (PRAC) List of questions to the Paediatric Committee (PDCO)

Summary of committee discussion:

The Committee noted the 'PRAC List of Questions (LoQ) to be addressed by the PDCO for fusafungine'.

Koenraad Norga was appointed as PDCO expert to coordinate the answers to PRAC. PDCO members were invited to send comments to the PDCO expert in advance of the PDCO November 2015 plenary meeting.

9.2.3. Draft Scientific Guideline on Post-authorisation efficacy studies (PAES)

Summary of committee discussion:

Postponed to PDCO November 2015 ORGAM meeting.

9.2.4. Announcement of Review and Learning Meeting to be organised in Netherlands on 1-3 June 2016

PDCO Member: Hendrik van den Berg

Summary of committee discussion:

The Committee was invited to attend, on 1-3 June 2016, the Strategic Review and Learning Meeting organised by the Medicines Evaluation Board in Utrecht (Netherlands) under the auspices of the Dutch presidency of the Council of the EU.

9.2.5. Ondansetron (NAP) - PI changes on paediatric overdose recommended

Summary of committee discussion:

The PDCO discussed and supported the changes to the Product information as proposed by the PRAC to inform about adverse reactions in children from an overdose.

9.3. Coordination with EMA Working Parties / Working Groups / Drafting Groups

9.3.1. Non-clinical Working Group: D30 Products identified

PDCO member: Jacqueline Carleer

Summary of committee discussion:

The chairperson of the Non-clinical Working Group (NcWG) of the PDCO identified relevant products for the group discussion in preparation of the November 2015 PDCO plenary discussion.

9.3.2. Formulation Working Group

PDCO member: Brian Aylward

Summary of committee discussion:

Documents tabled for information.

9.3.3. Draft mandate, objectives and rules of procedure for PDCO Formulation Working Group and PDCO Non-Clinical Working Group

PDCO members: Brian Aylward and Jacqueline Carleer

Summary of committee discussion:

The Committee discussed and then adopted the two mandates.

9.3.4. Inventory of paediatric therapeutic needs – gastroenterology

PDCO member: Birka Lehmann

Summary of committee discussion:

The final 'Inventory of paediatric therapeutic needs – Gastroenterology' was adopted for publication following the review of comments received during the public consultation phase. The Committee also adopted for publication a response document summarising the PDCO's review of the public comments.

9.4. Cooperation within the EU regulatory network

9.4.1. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA)

None

9.4.2. Involvement of young people in PDCO's activities

Summary of committee discussion:

Dr Pamela Dicks, Manager of the Scottish Clinical Research Network at the Royal Aberdeen Children's Hospital and Rafal Swierzewski, member of EMA's Patient and Consumer Working Party representing the European Cancer Patient Coalition, who is leading a young cancer patient group in Poland together with one young person from the Scottish young people advisory group presented to the committee their work and their proposals for how young people could contribute and provide their expertise to EMA's activities.

9.5. Cooperation with International Regulators

9.5.1. Report from the 'European Medicines Agency workshop on extrapolation across age groups' held on 30 September 2015

Summary of committee discussion:

The primary rationale for extrapolation is to avoid unnecessary studies in the target population for ethical reasons, for efficiency, and to allocate resources to areas where studies are most needed. In situations where the feasibility of studies is restricted, extrapolation principles may be applied for rational interpretation of the limited evidence in the target population in the context of data from other sources. As per the published European Medicines Agency (EMA) concept paper on extrapolation of efficacy and safety in medicine development, EMA is developing a framework for extrapolation approaches that are considered scientifically valid and reliable to support medicine authorisation. With the aim of developing the regulatory framework the Agency hosted an EMA expert workshop on 30 September 2015. The workshop was attended by experts from the EU regulatory network representing PDCO, CHMP, PRAC, SAWP (Scientific Advice Working Party), BSWP (Biostatistics Working Party), Pharmacokinetics Working Party (PKWP), Modelling and Simulation Working Group (MSWG), as well as experts from Academia and non-EU regulatory agencies (U.S. Food and Drug Administration, Health Canada, Brazil and Japan).

9.5.2. Report from the 'European Forum for Good Clinical Practice (EFGCP)/ Drug Information Association (DIA)/European Medicines Agency (EMA) Annual Conference on Better Medicines for Children' held on 1-2 October 2015

PDCO Chairperson: Dirk Mentzer

Summary of committee discussion:

The Committee was informed about the main topics addressed during this Conference.

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

None

9.7. PDCO work plan

None

9.8. Planning and reporting

None

9.9. PDCO ORGAM

None

9.10. Others

9.10.1. Use of comparators in trials - lessons learned during project 'Global Research in Paediatrics' (GRIP)

Guest speaker: Lauren Kelly

Summary of committee discussion:

The Committee heard a summary of the findings from the project.

9.10.2. Update of the European Commission (EC) on the economic study project

Summary of committee discussion:

The Committee was updated on the EC timelines for receiving the results of the economic study project to inform the planned EC's 10 years report since the Paediatric Regulation came into force.

10. Any other business

10.1. None

11. Breakout sessions

11.1.1. Paediatric oncology

Action: For discussion on Thursday, 19:00 - 19:30, room 2E

The group discussed information from recent and for forthcoming public meetings.

11.1.2. Neonatology

The meeting was cancelled.

12. List of participants

List of participants including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 7-9 October 2015 meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Dirk Mentzer	Chair	Germany	No interests declared	
Karl-Heinz Huemer	Member	Austria	No interests declared	
Koenraad Norga	Member (Vice-Chair)	Belgium	No restrictions applicable to this meeting	
Jacqueline Carleer	Alternate	Belgium	No restrictions applicable to this meeting	
Suzana Mimica Matanovic	Member	Croatia	No interests declared	
Georgios Savva	Member	Cyprus	No interests declared	
Jaroslav Sterba	Member	Czech Republic	No interests declared	
Marianne Orholm	Member	Denmark	No interests declared	
Marta Granström	Alternate	Denmark	No interests declared	
Irja Lutsar	Member	Estonia	No interests declared	
Jana Lass	Alternate	Estonia	No interests declared	
Ann Marie Kaukonen	Member	Finland	No interests declared	
Maija Pihlajamaki	Alternate	Finland	No interests declared	
Sylvie Benchetrit	Member	France	No interests declared	
Birka Lehmann	Member	Germany	No interests declared	
Immanuel Barth	Alternate	Germany	No interests declared	
Grigorios Melas	Member	Greece	No interests declared	
Ágnes Gyurasics	Member (CHMP member)	Hungary	No interests declared	
Brian Aylward	Member	Ireland	No interests declared	
Francesca Rocchi	Alternate	Italy	No restrictions applicable to this meeting	
Dina Apele-Freimane	Member	Latvia	No interests declared	
Hendrik van den Berg	Member	Netherlands	No interests declared	
Siri Wang	Member	Norway	No interests declared	
Marek Migdal	Member	Poland	No restrictions applicable to this	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
			meeting	
Jolanta Witkowska-Ozogowska	Alternate	Poland	No interests declared	
Helena Fonseca	Member	Portugal	No interests declared	
Hugo Tavares	Alternate	Portugal	No interests declared	
Dana Gabriela Marin	Member (CHMP alternate)	Romania	No interests declared	
Stefan Grosek	Member	Slovenia	No interests declared	
Fernando de Andrés Trelles	Member	Spain	No interests declared	
Maria Jesús Fernández Cortizo	Alternate	Spain	No interests declared	
Ninna Gullberg	Member	Sweden	No restrictions applicable to this meeting	
Anna-Karin Hamberg	Alternate	Sweden	No restrictions applicable to this meeting	
Angeliki Siapkara	Member	United Kingdom	No interests declared	
Martina Riegl	Alternate	United Kingdom	No interests declared	
Riccardo Riccardi	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Maria Grazia Valsecchi	Alternate	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Paolo Paolucci	Alternate	Healthcare Professionals' Representative	No interests declared	
Johannes Taminiau	Member	Healthcare Professionals' Representative	No interests declared	
Doina Plesca	Alternate	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Paola Baiardi	Alternate	Patients' Organisation Representative	No interests declared	
Tsvetana Schyns-Liharska	Member	Patients' Organisation Representative	No restrictions applicable to this meeting	
Kerry Leeson-Beevers	Alternate	Patients' Organisation Representative	No restrictions applicable to this meeting	
Eeva Sofia Leinonen	Member	Committee for Herbal Medicinal Products	No interests declared	
Eleni Gaki	Expert - in	Medicines and	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
	person*	Healthcare Products Regulatory Agency		
Pamela Dicks	Expert - in person*	Scottish Children's Research Network	No interests declared	
Rafal Swierzewski	Alternate	Patients' and Consumers' Working Party	Interests declared	
Irina Rotariu	Expert - in person*	ScotCRN Young Person's Advisory Group	No interests declared	
Kelly Lauren	Guest speaker-via TC*		No interests declared	
A representative from the European Commission attended the meeting.				
Meeting run with support from relevant EMA staff				

* Experts were only evaluated against the agenda topics or activities they participated in.

13. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP)
The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (section 6 Discussion on the applicability of class waiver)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived**.** For more information on the classes of diseases subject to waivers, see class waivers.

Annual reports on deferrals (section 8)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/